Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

22.2%

2 terminated/withdrawn out of 9 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

6 of 6 completed trials have results

Key Signals

6 with results

Enrollment Performance

Analytics

Phase 2
6(66.7%)
Phase 1
3(33.3%)
9Total
Phase 2(6)
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials
NCT03149445Phase 2Completed

Co-administration of Tesofensine/Metoprolol in Subjects With Prader-Willi Syndrome (PWS)

Role: lead

NCT03845075Phase 2Completed

48 Weeks, Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO)

Role: lead

NCT03488719Phase 1Completed

A Study to Examine the Effect of Tesofensine and Metoprolol on the 24-hour Mean Heart Rate

Role: lead

NCT05147415Phase 2Withdrawn

Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO)

Role: lead

NCT05198362Phase 2Withdrawn

Study of Tesomet With Open-label Extension in Subjects With Prader-Willi Syndrome

Role: lead

NCT04971135Phase 1Unknown

First-in-human Study of SAN711 in Healthy Participants

Role: lead

NCT02798627Phase 2Completed

Trial Of NS2359 For The Treatment of Cocaine Dependence

Role: collaborator

NCT02737891Phase 2Completed

Safety and Efficacy Study of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus

Role: lead

NCT03286829Phase 1Completed

Study to Investigate the Pharmacokinetic Profile

Role: lead

All 9 trials loaded